Clinical safety of biosimilar recombinant human erythropoietins

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 819-840

  Abraham, Ivo ^a   MacDonald, Karen ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

biosimilar pharmaceuticals; biosimilars; drug safety; erythropoietin; recombinant proteins; safety

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTHRALGIA; CANCER PATIENT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; HEALTH PROGRAM; HEART INFARCTION; HUMAN; IMMUNOGENICITY; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; LYMPHOMA; MORTALITY; MULTIPLE MYELOMA; NAUSEA; OBSERVATIONAL STUDY; PARESTHESIA; RENAL ANEMIA; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; DRUG HYPERSENSITIVITY; DRUG MONITORING; ERYTHROPOIETIN; HEMATINICS; HUMANS; INCIDENCE; PHARMACOVIGILANCE; RECOMBINANT PROTEINS; VENOUS THROMBOEMBOLISM;

EID: 84865461168     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.712681     Document Type: Review

References (62)

1. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 1985;22:7580-4 (Pubitemid 16204391)
2. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8 (Pubitemid 17052741)
3. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96:937-42
4. Lonneman G, Macdougall IC. Biosimilar epoetins in renal anemia. Current status and insights from European practice. Eur Nephrol 2011;5:101-7
5. Schellekens H. How similar do 'biosimilars' need to be? Nature Biotech 2004;22:1357-9 (Pubitemid 39482853)
6. Singh AK. Biosimilars: what are the issues? Available from: http://www.patientsorganizations.org/showarticle.pl?id=766. [Last accessed 23 July 2012]
7. Schellekens H. Biosimilar proteins: how similar are they? Eur J Hosp Pharm 2004;3:43-7
8. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954-62 (Pubitemid 40917928)
9. Deechongkit S, Aoki KH, Park SS, et al. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 2006;95:1931-43 (Pubitemid 44433025)
10. Brinks V, Hawe A, Basmeleh AHH, et al. Quality of original and biosimilar epoetin products. Pharm Res 2011;28:386-93
11. For HX575. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000725/human-med-000675.jsp&murl=menus/ medicines/medicines.jsp&mid=WC0b01ac058001d125 Last accessed 23 July 2012]
12. For SB309. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000872/human-med-001031.jsp&mid= WC0b01ac058001d124 [Last accessed 23 July 2012]
13. For XM01. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/001033/human-med-001204.jsp&mid= WC0b01ac058001d124 [Last accessed 23 July 2012]
14. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2(suppl 1):i27-36
15. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 2003;23:254-6 (Pubitemid 34655726)
16. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11 (Pubitemid 32050471)
17. Gershon SK, Luksenburg H, Coté TR, et al. Pure red cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-5
18. Bennett CL, Luminari S, Nissenson AR, et al. Pure red cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8 (Pubitemid 39288166)
19. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80 (Pubitemid 40425360)
20. Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 2009;14(suppl 1):1-5
21. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24 (Pubitemid 351397066)
22. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
23. Aapro MS, Birgegård G, Bokemeyer C, et al. Erythropoietins should be used according to guidelines. Lancet Oncol 2008;9:412-13 (Pubitemid 351618079)
24. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomized controlled trial. BMC Clin Pharmacol 2009;9:10
25. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Biosimilarity of HX575 (recombinant human epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther 2009;47:391-401
26. Haag-Weber M, Vetter A, Thyroff-Friesinger U. INJ-Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72:380-90
27. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anemia in patients with solid tumours. Onkologie 2009;32:168-74
28. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 2009;83:122-30
29. Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamics profiles of one US-marketed and two European-marketed epoetin alfas. A randomized prospective study. Drugs R D 2011;11:61-75
30. Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity, and efficacy of subcutaneous biosimilar epoetin - a (HX575) in non-dialysis patients with renal anemia: a multicentre, randomized, double-blind study. Clin Nephrol 2012;77:8-17
31. Kerkhofs L, Boschetti G, Lugini A, et al. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy induced anemia: real-life clinical experience. Fut Oncol 2012;Published online 23 March 2012
32. Gesualdo L, London G, Turner M, et al. A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anemia in hemodialysis patients: background and methodology of the MONITOR-CKD5 study. Intern Emerg Med 2011;Published online 18 May 2011
33. Hörl WH, Locatelli F, Haag-Weber M, et al. Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10 - 12 g/dL. Clin Nephrol 2012;78:24-32
34. Seidl A, X M, Fischer R, et al. Tungsten-mediated unfolding and aggregation of epoetin alfa in prefilled syringes as root cause for the occurrence of neutralising antibodies in an investigational clinical trial of subcutaneous administration. Pharm Res 2011;Published online 18 November 2011
35. Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: a monocentric, double-blind, randomized, single dose, three-period cross-over trial in healthy volunteers. Arzneimittelforschung 2008;58:220-4 (Pubitemid 351798782)
36. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of anemia. Curr Med Res Opin 2008;24:625-37 (Pubitemid 351428973)
37. Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin 2008;24:1407-15 (Pubitemid 351741574)
38. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, et al. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008;25:1215-28
39. Tzekova V, Mihaylov G, Elezovic I, Koytchev R. Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anemia. Curr Med Res Opin 2009;25:1689-97
40. Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: a monocentric, open, randomized, single dose, two-period cross-over trial in healthy volunteers. Arzneimittelforschung 2008;58:215-19 (Pubitemid 351798781)
41. Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and epoetin alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010;27:105-17
42. Wiȩcek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia patients on dialysis: posthoc analysis. Adv Ther 2010;27:941-52
43. Lonneman G, Wrenger E. Biosimilar epoetin zeta in nephrology - a single dialysis center experience. Clin Nephrol 2011;75:59-62
44. Gertz B, Kohler E, Kes P, et al. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin 2010;26:2393-402
45. Tjulandin SA, Bias P, Elsässer R, et al. Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised control trial. Arch Drug Inf 2010;3:45-53
46. Tjulandin SA, Bias P, Elsässer R, et al. Epoetin theta with a new dosing schedule in anaemic cancer patients receiving non-platinum chemotherapy: a randomised control trial. Arch Drug Inf 2010;4:33-41
47. Hörl WH, Jacobs C, Macdougall IC, et al. European Best Practice Guidelines 17-18: Adverse effects. Nephrol Dial Transplant 2000;15(suppl 4):51-6
48. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75 (Pubitemid 34441737)
49. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1385-7
50. Macdougall I, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis- stimulating agents: new insights. Kidney Int 2012;81:727-32
51. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008;74:1617-22
52. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80:88-92
53. Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004;22:175-80 (Pubitemid 38142303)
54. For the DOPPS study. Available from: http://www.dopps.org [Last accessed 23 July 2012]
55. For the ESAM study. European survey on anaemia management. Nephrol Dial Transplant 2000;15(Suppl 4):1-76
56. Hörl WH, Macdougall IC, Rossert J, et al. Predialysis survey on anemia management: patient referral. Am J Kidn Dis 2003;41:49-61 (Pubitemid 36043351)
57. Valderrábano F, Hörl WH, Macdougall IC, et al. Pre-dialysis survey on anemia management. Nephrol Dials Transplant 2003;18:89-100
58. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Canc 2004;40:2293-306 (Pubitemid 39348881)
59. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns, outcomes, and response rates in the management of cancer-related anemia in Europe: findings from the Anemia Cancer Treatment (A. C.T.) study. Eur J Canc 2009; 45:1603-15
60. Aapro M, Ludwig H, Bokemeyer C, et al. Modeling of outcomes and response rates to treatment with erythropoiesis stimulating agents in cancer patients with anemia: findings from the Anemia Cancer Treatment (A.C.T.) study. Ann Oncol 2009; 20:1714-21
61. Rosencher N, Kerkkamp H, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: Blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003;43:59-69
62. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507